CASBF.US CanSino Biologics Inc

Healthcare Pharmaceuticals USA Stocks
5.77 USD
Close of Nov 14, 2026
2.60 5.60
Market cap
USD 766M
P/E
103.3x
P/B
1.13x
ROE
0.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CASBF.US undervalued?

Graham number
Price5.77
Graham value2.54
Premium127.7%

CASBF.US trades 127.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CanSino Biologics Inc fundamental analysis

No fundamental analysis for CanSino Biologics Inc yet.

CanSino Biologics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CanSino Biologics Inc

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary va…

Full company profile